Boston Scientific Management
Management criteria checks 3/4
Boston Scientific's CEO is Mike Mahoney, appointed in Oct 2011, has a tenure of 14.08 years. total yearly compensation is $21.42M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $170.27M. The average tenure of the management team and the board of directors is 6.9 years and 6.9 years respectively.
Key information
Mike Mahoney
Chief executive officer
US$21.4m
Total compensation
| CEO salary percentage | 6.54% |
| CEO tenure | 14.1yrs |
| CEO ownership | 0.1% |
| Management average tenure | 6.9yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
Boston Scientific Q3: Operational Improvements Warrant An Upgrade To A Buy
Oct 24Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Jul 21
Returns At Boston Scientific (NYSE:BSX) Are On The Way Up
Jul 04Boston Scientific's (NYSE:BSX) Solid Earnings Have Been Accounted For Conservatively
May 08Boston Scientific Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 25Estimating The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)
Apr 23Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Apr 07Boston Scientific: Bright Future, Rather Pricey
Mar 18Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
Mar 05Boston Scientific (NYSE:BSX) Has More To Do To Multiply In Value Going Forward
Jan 29Is It Time To Consider Buying Boston Scientific Corporation (NYSE:BSX)?
Jan 15Boston Scientific Standing Apart As A Rare Med-Tech Growth Story
Jan 14Calculating The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)
Jan 02Do Boston Scientific's (NYSE:BSX) Earnings Warrant Your Attention?
Dec 19Why The Fundamentals Make Me Bullish On Boston Scientific
Oct 31Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Oct 23Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
Sep 20Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$3b |
| Jun 30 2025 | n/a | n/a | US$3b |
| Mar 31 2025 | n/a | n/a | US$2b |
| Dec 31 2024 | US$21m | US$1m | US$2b |
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$19m | US$1m | US$2b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$861m |
| Mar 31 2023 | n/a | n/a | US$846m |
| Dec 31 2022 | US$17m | US$1m | US$642m |
| Sep 30 2022 | n/a | n/a | US$596m |
| Jun 30 2022 | n/a | n/a | US$828m |
| Mar 31 2022 | n/a | n/a | US$754m |
| Dec 31 2021 | US$16m | US$1m | US$985m |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$526m |
| Mar 31 2021 | n/a | n/a | US$201m |
| Dec 31 2020 | US$14m | US$667k | -US$115m |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$4b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$16m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$14m | US$1m | US$2b |
Compensation vs Market: Mike's total compensation ($USD21.42M) is above average for companies of similar size in the US market ($USD13.47M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
CEO
Mike Mahoney (60 yo)
Mr. Michael F. Mahoney, also known as Mike, has been Independent Director of CVS Health Corporation since November 01, 2023 and serves as its Lead Independent Director since March 20, 2025. He has been Cha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 14.1yrs | US$21.42m | 0.11% $ 170.3m | |
| Senior Advisor | less than a year | US$6.69m | 0.015% $ 22.7m | |
| Executive VP & Group President of Cardiology | 15.8yrs | US$6.34m | 0.012% $ 18.5m | |
| Executive VP & President of Peripheral Interventions | 12.8yrs | US$4.03m | 0.0017% $ 2.6m | |
| Executive VP and Group President of MedSurg & Asia Pacific | 9.3yrs | US$5.01m | 0.0025% $ 3.7m | |
| Executive VP & CFO | less than a year | no data | 0.0024% $ 3.6m | |
| Executive Vice President of Global Operations | 3.5yrs | no data | 0.0013% $ 1.9m | |
| Senior VP | 1.7yrs | no data | 0.000030% $ 44.8k | |
| Senior VP | 4.4yrs | no data | 0.0023% $ 3.4m | |
| General Manager of Global Sales & Marketing | no data | no data | no data | |
| Senior VP & Chief Human Resources Officer | no data | no data | no data | |
| Senior Vice President of Global Government Affairs | 18.8yrs | no data | no data |
Experienced Management: BSX's management team is seasoned and experienced (6.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 13yrs | US$21.42m | 0.11% $ 170.3m | |
| Lead Independent Director | 11.7yrs | US$376.67k | 0.0012% $ 1.8m | |
| Independent Director | 9.6yrs | US$356.67k | 0.0025% $ 3.7m | |
| Independent Director | 9.3yrs | US$351.67k | 0.00014% $ 208.9k | |
| Independent Director | 4.4yrs | US$361.67k | 0.0028% $ 4.2m | |
| Independent Director | 1.5yrs | US$292.51k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$215.08k | 0.00038% $ 567.1k | |
| Independent Director | 16.6yrs | US$356.67k | 0.0037% $ 5.5m | |
| Independent Director | 2.4yrs | US$336.35k | 0.00056% $ 835.8k | |
| Independent Director | 2.4yrs | US$336.35k | 0.00045% $ 671.6k |
Experienced Board: BSX's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 23:18 |
| End of Day Share Price | 2025/11/03 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boston Scientific Corporation is covered by 61 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| David Rescott | Baird |
| Matthew Miksic | Barclays |